LEMAITRE VASCULAR INC

LeMaitre Vascular, Inc. announced that its Chief Financial Officer, Dorian LeBlanc, will participate in three upcoming investor conferences. These include the Stifel 2026 Healthcare Conference on November 12, 2026, the Jefferies 2026 Global Healthcare Conference on November 17, 2026, and the Piper Sandler 38th Annual Healthcare Conference on December 3, 2026. LeMaitre Vascular is a provider of devices, implants, and services for the treatment of peripheral vascular disease.

LeMaitre Vascular, Inc. filed its quarterly report for the period ending September 30, 2026. The company reported an increase in net sales for both the third quarter and the first nine months of the year compared to the previous year. However, diluted earnings per share saw a decrease in the third quarter, though it increased for the nine-month period. The balance sheet shows growth in total assets and stockholders' equity, with a slight increase in total liabilities. The company also announced a quarterly cash dividend of $0.25 per share.

LeMaitre Vascular, Inc. reported strong preliminary financial and operational results for the third quarter of 2026. Sales increased by 11% year-over-year to $68.0 million, with organic growth of 12%. Diluted EPS was $0.65, up 5% year-over-year on an adjusted basis. The company also announced a quarterly dividend of $0.25 per share and provided guidance for Q4 and the full year 2026. Additionally, LeMaitre completed the acquisition of certain vascular assets from B. Braun for $19.2 million in October 2026.

LeMaitre Vascular, Inc. announced that its management will participate in investor meetings at the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference. The meetings are scheduled for Tuesday, August 11, 2026, providing an opportunity for investors to engage with the company's leadership.

LeMaitre Vascular reported strong financial results for the second quarter and first half of 2026. Net sales for Q2 increased 9.6% to $70.4 million, while net income surged 23.7% to $17.1 million, leading to a diluted EPS of $0.74. For the first six months, net sales grew 10.3% to $136.9 million and net income climbed 32.0% to $32.7 million. The company also declared a quarterly cash dividend of $0.25 per share, a 25% increase from the prior year, and adjusted its convertible senior notes conversion rate accordingly.

LeMaitre Vascular, Inc. reported strong preliminary financial results for Q2 2026, with sales increasing 10% to $70.4 million and diluted EPS rising 23% to $0.74. The company also announced a quarterly dividend of $0.25 per share and provided guidance for Q3 and the full year 2026. Key drivers included robust Artegraft sales and international expansion efforts, contributing to improved gross and operating margins.

LeMaitre Vascular, Inc. reported strong Q2 2026 results, with sales increasing 10% to $70.4 million and diluted EPS growing 23% to $0.74. The company's gross margin expanded to 72.1%, and operating income rose 26%. Artegraft sales were a significant driver, growing 34% and becoming the fastest-growing product. The Board also approved a quarterly dividend of $0.25 per share and provided positive full-year 2026 guidance, with sales expected to reach a midpoint of $276.3 million.

LeMaitre Vascular, Inc. announced it will release its second quarter 2026 financial results on Tuesday, August 4, 2026, after the market closes. The company has scheduled a conference call for 5:00 PM EDT on the same day to discuss the results, business highlights, and company outlook. Interested parties can register online to access the live call or view the audio webcast via replay.

LeMaitre Vascular, Inc. announced that its management will participate in two investor conferences in June. The company will hold a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026, and present at the Goldman Sachs Annual Global Healthcare Conference on June 10, 2026.

LeMaitre Vascular, Inc. announced that its management will present at the Bank of America Healthcare Conference on May 13, 2026, at 5:15 PM PT. The company is a provider of devices, implants, and services for the treatment of peripheral vascular disease, focusing on vascular surgeons.